BioCryst Pharmaceuticals, Inc. (BMV:BCRX)
Mexico
· Delayed Price · Currency is MXN 138.00
0.00 (0.00%)
At close: Apr 29, 2025
BioCryst Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Revenue | 450.71 | 331.41 | 270.83 | 157.17 | 17.81 | Upgrade
|
| Revenue Growth (YoY) | 36.00% | 22.37% | 72.31% | 782.38% | -63.53% | Upgrade
|
| Cost of Revenue | 185.92 | 216.65 | 259.89 | 216.07 | 124.64 | Upgrade
|
| Gross Profit | 264.79 | 114.76 | 10.94 | -58.9 | -106.83 | Upgrade
|
| Selling, General & Admin | 266.07 | 213.54 | 159.37 | 118.82 | 62.9 | Upgrade
|
| Operating Expenses | 266.07 | 213.54 | 159.37 | 118.82 | 62.9 | Upgrade
|
| Operating Income | -1.28 | -98.78 | -148.44 | -177.72 | -169.73 | Upgrade
|
| Interest Expense | -98.52 | -108.24 | -99.09 | -59.29 | -14.5 | Upgrade
|
| Interest & Investment Income | 14.75 | 15.78 | 5.13 | 0.06 | 0.53 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.64 | -1.04 | -1.98 | -0.7 | -0.97 | Upgrade
|
| EBT Excluding Unusual Items | -85.69 | -192.28 | -244.38 | -237.65 | -184.67 | Upgrade
|
| Merger & Restructuring Charges | -1.26 | -3.38 | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | - | 0 | - | Upgrade
|
| Asset Writedown | - | -1.55 | - | - | - | Upgrade
|
| Legal Settlements | - | - | - | - | 3.87 | Upgrade
|
| Other Unusual Items | - | -29.02 | - | 55.84 | -2.01 | Upgrade
|
| Pretax Income | -86.95 | -226.23 | -244.38 | -181.81 | -182.81 | Upgrade
|
| Income Tax Expense | 1.93 | 0.31 | 2.73 | 2.25 | - | Upgrade
|
| Net Income | -88.88 | -226.54 | -247.12 | -184.06 | -182.81 | Upgrade
|
| Net Income to Common | -88.88 | -226.54 | -247.12 | -184.06 | -182.81 | Upgrade
|
| Shares Outstanding (Basic) | 207 | 192 | 186 | 179 | 167 | Upgrade
|
| Shares Outstanding (Diluted) | 207 | 192 | 186 | 179 | 167 | Upgrade
|
| Shares Change (YoY) | 7.54% | 3.38% | 3.79% | 7.08% | 44.70% | Upgrade
|
| EPS (Basic) | -0.43 | -1.18 | -1.33 | -1.03 | -1.09 | Upgrade
|
| EPS (Diluted) | -0.43 | -1.18 | -1.33 | -1.03 | -1.09 | Upgrade
|
| Free Cash Flow | -53.14 | -97.31 | -163.2 | -144.54 | -135.62 | Upgrade
|
| Free Cash Flow Per Share | -0.26 | -0.51 | -0.88 | -0.81 | -0.81 | Upgrade
|
| Gross Margin | 58.75% | 34.63% | 4.04% | -37.48% | - | Upgrade
|
| Operating Margin | -0.28% | -29.81% | -54.81% | -113.07% | -952.90% | Upgrade
|
| Profit Margin | -19.72% | -68.36% | -91.25% | -117.11% | -1026.35% | Upgrade
|
| Free Cash Flow Margin | -11.79% | -29.36% | -60.26% | -91.97% | -761.41% | Upgrade
|
| EBITDA | 1.73 | -95.91 | -146.18 | -176.83 | -168.98 | Upgrade
|
| EBITDA Margin | 0.39% | -28.94% | -53.98% | -112.51% | - | Upgrade
|
| D&A For EBITDA | 3.01 | 2.87 | 2.25 | 0.89 | 0.75 | Upgrade
|
| EBIT | -1.28 | -98.78 | -148.44 | -177.72 | -169.73 | Upgrade
|
| EBIT Margin | -0.28% | -29.81% | -54.81% | -113.07% | - | Upgrade
|
| Revenue as Reported | - | - | - | - | 17.81 | Upgrade
|
| Advertising Expenses | 13.57 | 14.4 | 14.89 | 5.71 | 6.57 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.